Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
McKinsey
Mallinckrodt
Teva
McKesson
Cantor Fitzgerald

Generated: May 25, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,452,872

« Back to Dashboard

Which drugs does patent 7,452,872 protect, and when does it expire?

Patent 7,452,872 protects GIAZO and COLAZAL and is included in two NDAs.

Protection for COLAZAL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-seven patent family members in twelve countries.

Summary for Patent: 7,452,872
Title:Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Abstract:A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.
Inventor(s): Johnson; Lorin (Palo Alto, CA)
Assignee: Salix Pharmaceuticals, Inc. (Morrisville, NC)
Application Number:11/835,897
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,452,872
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,452,872
Patent Claim Types:
see list of patent claims
Use; Dosage form; Formulation;

Drugs Protected by US Patent 7,452,872

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Valeant Pharms Intl GIAZO balsalazide disodium TABLET;ORAL 022205-001 Feb 3, 2012 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS ➤ Try a Free Trial
Valeant Pharms Intl COLAZAL balsalazide disodium CAPSULE;ORAL 020610-001 Jul 18, 2000 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 7,452,872

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006282865 ➤ Try a Free Trial
Australia 2007322362 ➤ Try a Free Trial
Brazil PI0615195 ➤ Try a Free Trial
Brazil PI0717859 ➤ Try a Free Trial
Canada 2620091 ➤ Try a Free Trial
Canada 2668441 ➤ Try a Free Trial
Canada 2816276 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Healthtrust
Boehringer Ingelheim
Deloitte
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.